Bone metastases in biliary cancers: A multicenter retrospective survey

Santini, Daniele; Brandi, Giovanni; Aprile, G.; Russano, Marco; Cereda, Stefano; Leone, Francesco; Fornaro, Lorenzo; Scartozzi, Mario; Silvestris, Nicola; Barni, Sandro; Pantano, Francesco; Vincenzi, Bruno; Palloni, Andrea; Frega, Giorgio; Casagrande, M.; Ferrari, Laura; Dadduzio, Vincenzo; Intini, Rossana; Filippi, Roberto; Vasile, Enrico; Vivaldi, Caterina; Faloppi, Luca; Brunetti, Oronzo; Reni, Michele; Aglietta, Massimo; Tonini, Giuseppe

doi:10.1016/j.jbo.2017.11.006

Cited by 7 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A milestone in the clinical management of skeletal related events (SRE) in cancer, including SMUP, were the discovery of bisphosphonates and SRE-directed therapies. Bisphosphonates are effective in increasing survival and reducing skeletal complications, including hypercalcemia, delaying the time of appearance of skeletal complications, and reducing bone pain in patients with metastases, particularly intravenous ones [88,89,90,91,92].…”

Section: Clinical Management For Skeletal Metastasis Of Unknown Prmentioning

confidence: 99%

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview

Argentiero

Solimando

Brunetti

et al. 2019

Cancers

View full text Add to dashboard Cite

Skeletal metastases of unknown primary (SMUP) represent a clinical challenge in dealing with patients diagnosed with bone metastases. Management of these patients has improved significantly in the past few years. however, it is fraught with a lack of evidence. While some patients have achieved impressive gains, a more systematic and tailored treatment is required. Nevertheless, in real-life practice, the outlook at the beginning of treatment for SMUP is decidedly somber. An incomplete translational relevance of pathological and clinical data on the mortality and morbidity rate has had unsatisfactory consequences for SMUP patients and their physicians. We examined several approaches to confront the available evidence; three key points emerged. The characterization of the SMUP biological profile is essential to driving clinical decisions by integrating genetic and molecular profiles into a multi-step diagnostic work-up. Nonetheless, a pragmatic investigation plan and therapy of SMUP cannot follow a single template; it must be adapted to different pathophysiological dynamics and coordinated with efforts of a systematic algorithm and high-quality data derived from statistically powered clinical trials. The discussion in this review points out that greater efforts are required to face the unmet needs present in SMUP patients in oncology.

show abstract

Section: Clinical Management For Skeletal Metastasis Of Unknown Prmentioning

confidence: 99%

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview

Argentiero

Solimando

Brunetti

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Another previous study found that most of the metastatic lesions from CCA had mixed osteolytic and osteoblastic patterns on the CT images (40.8%) and increased uptake on planar BS (93.6%) 4 , while another study found lytic lesions were the most common metastatic type, accounting for 57.5% of the patients. 15 Thus, the benefit of add-on SPECT/CT is still unclear and needs to be further investigated.…”

Section: Siurai N Et Al Factors Associated With Positive Bone Scan In...mentioning

confidence: 99%

“…This finding concurs with a previous study which found that bone metastasis was synchronous with visceral metastases in 48 of 137 cases (35.0%) of patients with biliary cancers. Furthermore, bone metastasis was subsequently seen in 82 patients (60.0%) who had visceral disease 15 . This finding can be explained by hematogenous spread which is the common route of metastasis to bone or other visceral organs 16 .…”

Section: Siurai N Et Al Factors Associated With Positive Bone Scan In...mentioning

confidence: 99%

Factors Associated with Bone Scintigraphy Positivity in Cholangiocarcinoma

Siurai

Twinprai

Theerakulpisut

et al. 2023

J Health Sci Med Res

View full text Add to dashboard Cite

Objective: To examine factors associated with bone scintigraphy (BS) positivity in cases with cholangiocarcinoma (CCA) to help assess appropriate utilization of BS in CCA patients. Material and Methods: This cross-sectional study enrolled CCA patients who underwent BS for detection of bone metastasis between January 2012 and July 2020. The BS images were reviewed by two nuclear medicine physicians to assess BS positivity. Factors including tumor location, T stage, regional lymph node metastasis, other distant metastases, and serum carbohydrate antigen 19-9 (CA19-9) were evaluated. Associations between covariates and positive BS were analyzed using bivariate and multiple logistic regressions. Results: Among 158 CCA patients, 70 (44.3%), 84 (53.2%), and 4 (2.5%) had positive, negative, and equivocal BS, respectively. Of all 70 positive cases, 50 cases (71.4%) had multiple metastatic lesions. The spine was the most common metastatic site (n=55, 78.6%). After exclusion of equivocal cases, 154 were included in the regression models. In bivariate logistic regression, the factors associated with BS positivity were intrahepatic tumor location (OR=2.18, p-value=0.039) and other distant metastasis (OR=2.08, p-value=0.028). Further analysis using multiple logistic regression showed only other distant metastasis was associated with positive BS (OR=2.66, p-value=0.008). Conclusion: There was a significant association between other distant metastasis and BS positivity in CCA patients. This factor should be considered as a clinical indication for requesting BS in this group of patients.

show abstract

“…of appearance of skeletal complications and reducing bone pain in patients with metastases, particularly intravenous ones. [78][79][80][81][82] Denosumab is a viable subcutaneous alternative and a preferred option where it is possible that it has shown moderate greater efficacy than Zoledronic acid in reducing skeletal events (excluding hypercalcemia). [83,84] Several molecules with direct or indirect effects on the bone metastases progression of solid tumors are currently investigated in several clinical trials.…”

Section: Bisphosphonates and Bone Disease Modifying Agentsmentioning

confidence: 99%

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview

Argentiero¹,

Solimando²,

Brunetti³

et al. 2019

Preprint

View full text Add to dashboard Cite

Skeletal metastases of unknown primary (SMUP) represent a clinical challenge dealing with patients diagnosed with bone metastases. The management have improved significantly in the past years, however fraught with lack of evidences, approach to these patients held out hope for more systematic and tailored treatment—and some patients can achieve impressive gains. Nevertheless, in real-life practice the outlook at the beginning of the take in charge of SMUP is decidedly more somber. An incomplete translational relevance of pathological and clinical data on the mortality and morbidity rate has had unsatisfactory consequences for SMUP patients and their physicians. We examined several approaches to confront the available evidences and highlighted three key points that emerge. The characterization of the SMUP biologic profile is essential to drive clinical decisions, integrating genetic and molecular profile into a multi-step diagnostic work-up. Nonetheless, pragmatic investigation plan and therapy of SMUP cannot follow a single template; it must be adapted to different pathophysiological dynamics and coordinated with efforts of a systematic algorithm and high-quality data derived from statistically powered clinical trials within. This review argues that greater efforts are required to face the unmet need dealing with SMUP patients in oncology. Finally, we provide an original functional network analysis, identifying novel therapeutic targets.

show abstract

Bone metastases in biliary cancers: A multicenter retrospective survey

Abstract: HighlightsNatural history of biliary cancers metastatic to boneThe role of skeletal events in patients with biliary cancerBiliary cancer and bone metastases: role of bisphosphonates

Cited by 7 publications

References 14 publications

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview

Factors Associated with Bone Scintigraphy Positivity in Cholangiocarcinoma

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview

Contact Info

Product

Resources

About